Abstract

IDEX Corp will report quarterly results on July 29, 2026 Pre-MKt; current consensus calls for revenue of 905.52 million US dollars (up 5.45% year over year) and adjusted EPS of 2.11 (up 5.93% year over year), with investors monitoring margins, order quality, and segment mix.

Market Forecast

Consensus for the upcoming quarter indicates revenue of 905.52 million US dollars, EBIT of 191.38 million US dollars, and adjusted EPS of 2.11, implying year-over-year growth of 5.45%, 4.44%, and 5.93%, respectively. While the latest projections do not quantify gross margin or net margin for this quarter, commentary around price discipline and cost containment suggests a broadly stable margin profile versus recent trends. Management’s last update on the full-year outlook—an adjusted EPS range of 8.35 to 8.55—frames expectations for steady sequential execution through the midyear period.

Across the company’s primary businesses, revenue last quarter totaled 886.90 million US dollars, and the forward setup points to modest growth led by health- and science-exposed demand and steady orders in flow solutions. Within that mix, Health & Science Technologies stands out as the largest and most resilient platform at 398.40 million US dollars last quarter; sell-side previews anticipate low- to mid-single-digit year-over-year growth in this area near term, supported by service and consumables strength and stable project activity.

Last Quarter Review

IDEX Corp delivered revenue of 886.90 million US dollars, a gross profit margin of 44.89%, GAAP net profit attributable to shareholders of 120.00 million US dollars, a net profit margin of 13.53%, and adjusted EPS of 2.00, with year-over-year growth in revenue and adjusted EPS of 8.92% and 14.29%, respectively. A key financial highlight was EBIT of 213.60 million US dollars, up 11.83% year over year, with net income experiencing a 6.47% sequential decline as post-holiday volume normalization and timing of operating expenses weighed on quarter-on-quarter comparability. By business, Health & Science Technologies generated 398.40 million US dollars, Fluid & Metering Technologies delivered 301.50 million US dollars, and Fire & Safety/Diversified Products contributed 188.30 million US dollars, helping lift consolidated revenue by 8.92% year over year.

Current Quarter Outlook

Main business: Execution and mix support midyear growth

The company enters this quarter with a consensus revenue forecast of 905.52 million US dollars and adjusted EPS of 2.11, reflecting expectations for measured growth aided by pricing carryover, backlog conversion, and a disciplined cost structure. Within the core portfolio, order trends have been stabilizing, and mix continues to benefit from consumable and service components that tend to cushion cyclical volume swings in capital equipment. Management’s emphasis on pricing discipline has previously offset input variability; that same discipline, paired with easing inflation in select materials and logistics, should help preserve gross margin consistency even if volumes normalize unevenly across end uses this quarter. On operating expenses, incremental reinvestment for growth and new product initiatives is likely to be paced, maintaining leverage at a prudent level given top-line trajectories. EBIT is forecast at 191.38 million US dollars, up 4.44% year over year, which implies modest margin compression versus last quarter’s strong performance but consistent with steady midyear execution. Working capital has historically been well managed, and the typical midyear cadence suggests inventory and receivables will be aligned with shipment timing; the degree to which working capital conversion supports free cash flow is an area investors will watch for confirmation of guidance. Altogether, the forward setup suggests the company can meet modest top-line growth expectations while holding margin quality, especially if price-cost remains favorable and mix tilts toward higher value applications.

Most promising business: Health & Science Technologies

Health & Science Technologies posted 398.40 million US dollars of revenue last quarter and remains the most prominent growth engine heading into this print, underpinned by demand in life-science-adjacent tools, analytical workflows, and specialty components that are less exposed to short-cycle volatility. Analysts broadly expect low- to mid-single-digit year-over-year expansion for this platform in the current quarter, citing healthy service and consumables throughput, resilient aftermarket activity, and stability in key project funnels. Pricing remains a constructive contributor here; over recent quarters, the company has demonstrated the ability to hold price across differentiated subcategories where performance and reliability are essential, and that backdrop should continue to support margins even as volumes fluctuate by customer type. Order quality is a focal point: indications of backlog conversion alongside replenishment orders would signal normalization of purchasing patterns and reduce the risk of second-half growth dips. On profitability, incremental margin in this segment tends to benefit from the mix of high-value components and services; investors will be looking for commentary that corroborates stable cost absorption and disciplined overhead as shipment cadence steps through midyear. Should this platform continue to execute in line with expectations, it would provide a stabilizing base for consolidated earnings and help offset any unevenness in other areas of the portfolio.

Key stock-price drivers this quarter: Margins, order cadence, and capital deployment

The near-term stock reaction is most likely to hinge on margin durability and the tone of order intake across platforms. On margins, gross profit held at 44.89% last quarter and net margin at 13.53%; investors will look for signs that price realization and easing freight/materials can keep gross margin close to that neighborhood despite volume mix shifts. Any commentary quantifying the balance between price, mix, and input costs will be closely parsed to infer second-half run-rate profitability. Order cadence will be scrutinized for signals of breadth: ongoing demand in health- and science-addressable categories is expected to smooth variability, but confirmation of replenishment activity in flow metering and safety solutions would support confidence in the consensus revenue trajectory. Capital deployment is another swing factor: management’s previously discussed capital allocation priorities—organic reinvestment, disciplined M&A, dividends, and repurchases—frame potential upside levers. An update on the M&A pipeline or incremental buybacks would likely be received positively if accompanied by steady operating performance. Finally, qualitative color on backlog conversion and timing of larger projects can influence implied exit run rates for the year, which feeds into how investors calibrate the full-year EPS range of 8.35 to 8.55 against quarterly progression.

Analyst Opinions

The balance of recent sell-side commentary within the January 1, 2026 to July 22, 2026 window is bullish, with multiple institutions reiterating positive views and lifting price targets as near-term expectations consolidate around steady growth and solid margin quality. Notably, RBC Capital reaffirmed an Outperform stance and subsequently increased its price target to 252 US dollars, citing improved confidence in the company’s ability to translate backlog and pricing into consistent earnings delivery. Stifel Nicolaus maintained a Buy rating, underscoring the constructive risk-reward as expectations normalize and operational execution remains disciplined through midyear. Oppenheimer reiterated an Outperform and highlighted the portfolio’s balance and “reasonable” near-term expectations, pointing to a setup where incremental delivery on revenue and margin can sustain earnings progress. Across these positive opinions, analysts converge on three core points: near-term growth in the low- to mid-single-digit range looks achievable on current visibility, operational discipline should protect margins as mix evolves, and capital deployment continues to enhance per-share results.

From a modeling perspective, these bullish previews commonly embed the same contours visible in the market’s consensus: revenue around 905.52 million US dollars, EBIT near 191.38 million US dollars, and adjusted EPS of 2.11. The credibility of those figures rests on observed drivers in the last quarter—an 8.92% year-over-year revenue gain, 44.89% gross margin, and 2.00 adjusted EPS—which collectively signal that the company has been able to sustain throughput and hold profitability while absorbing sequential movements in net income. Where the bullish camp expands is on the incremental path from here: a clean margin bridge predicated on price discipline, productivity, and improving input dynamics; a mix framework that leans on more resilient health- and science-exposed demand; and a capital allocation plan that continues to support per-share growth via dividends and buybacks without compromising balance sheet flexibility. The net effect, in their view, is a setup where modest top-line growth can continue converting into stable or slightly improving earnings, keeping the company on pace with its full-year adjusted EPS framework.

These analysts also acknowledge typical midyear crosscurrents—such as potential timing noise in project shipments or temporary inventory adjustments by customers—but they see these as manageable within the current quarter’s forecast ranges. What they will look for on July 29, 2026 is confirmation of order breadth across the primary platforms and commentary that corroborates stable demand in health- and science-adjacent solutions. A reiteration of the full-year EPS range would likely be taken as validation that the second-half volume and margin assumptions remain intact, while even a modest raise would be interpreted as evidence of stronger backlog conversion or enhanced price-cost carryover. In sum, the prevailing institutional view into the print is positive: the company is expected to post a quarter that aligns with measured growth and margin steadiness, with the Health & Science Technologies platform offering the most attractive near-term mix and the consolidated business positioned to deliver on the consensus track for revenue and adjusted EPS.